415 related articles for article (PubMed ID: 31249028)
1. Passenger hotspot mutations in cancer driven by APOBEC3A and mesoscale genomic features.
Buisson R; Langenbucher A; Bowen D; Kwan EE; Benes CH; Zou L; Lawrence MS
Science; 2019 Jun; 364(6447):. PubMed ID: 31249028
[TBL] [Abstract][Full Text] [Related]
2. An extended APOBEC3A mutation signature in cancer.
Langenbucher A; Bowen D; Sakhtemani R; Bournique E; Wise JF; Zou L; Bhagwat AS; Buisson R; Lawrence MS
Nat Commun; 2021 Mar; 12(1):1602. PubMed ID: 33707442
[TBL] [Abstract][Full Text] [Related]
3. Identification of new driver and passenger mutations within APOBEC-induced hotspot mutations in bladder cancer.
Shi MJ; Meng XY; Fontugne J; Chen CL; Radvanyi F; Bernard-Pierrot I
Genome Med; 2020 Sep; 12(1):85. PubMed ID: 32988402
[TBL] [Abstract][Full Text] [Related]
4. An APOBEC3A hypermutation signature is distinguishable from the signature of background mutagenesis by APOBEC3B in human cancers.
Chan K; Roberts SA; Klimczak LJ; Sterling JF; Saini N; Malc EP; Kim J; Kwiatkowski DJ; Fargo DC; Mieczkowski PA; Getz G; Gordenin DA
Nat Genet; 2015 Sep; 47(9):1067-72. PubMed ID: 26258849
[TBL] [Abstract][Full Text] [Related]
5. Integrative genomic analyses of APOBEC-mutational signature, expression and germline deletion of APOBEC3 genes, and immunogenicity in multiple cancer types.
Chen Z; Wen W; Bao J; Kuhs KL; Cai Q; Long J; Shu XO; Zheng W; Guo X
BMC Med Genomics; 2019 Sep; 12(1):131. PubMed ID: 31533728
[TBL] [Abstract][Full Text] [Related]
6. An APOBEC cytidine deaminase mutagenesis pattern is widespread in human cancers.
Roberts SA; Lawrence MS; Klimczak LJ; Grimm SA; Fargo D; Stojanov P; Kiezun A; Kryukov GV; Carter SL; Saksena G; Harris S; Shah RR; Resnick MA; Getz G; Gordenin DA
Nat Genet; 2013 Sep; 45(9):970-6. PubMed ID: 23852170
[TBL] [Abstract][Full Text] [Related]
7. APOBEC3A catalyzes mutation and drives carcinogenesis in vivo.
Law EK; Levin-Klein R; Jarvis MC; Kim H; Argyris PP; Carpenter MA; Starrett GJ; Temiz NA; Larson LK; Durfee C; Burns MB; Vogel RI; Stavrou S; Aguilera AN; Wagner S; Largaespada DA; Starr TK; Ross SR; Harris RS
J Exp Med; 2020 Dec; 217(12):. PubMed ID: 32870257
[TBL] [Abstract][Full Text] [Related]
8. Quantification of ongoing APOBEC3A activity in tumor cells by monitoring RNA editing at hotspots.
Jalili P; Bowen D; Langenbucher A; Park S; Aguirre K; Corcoran RB; Fleischman AG; Lawrence MS; Zou L; Buisson R
Nat Commun; 2020 Jun; 11(1):2971. PubMed ID: 32532990
[TBL] [Abstract][Full Text] [Related]
9. Whole-genome mapping of APOBEC mutagenesis in metastatic urothelial carcinoma identifies driver hotspot mutations and a novel mutational signature.
Nakauma-González JA; Rijnders M; Noordsij MTW; Martens JWM; van der Veldt AAM; Lolkema MPJ; Boormans JL; van de Werken HJG
Cell Genom; 2024 Apr; 4(4):100528. PubMed ID: 38552621
[TBL] [Abstract][Full Text] [Related]
10. HotSpotAnnotations-a database for hotspot mutations and annotations in cancer.
Trevino V
Database (Oxford); 2020 Jan; 2020():. PubMed ID: 32386297
[TBL] [Abstract][Full Text] [Related]
11. Prediction of cancer driver mutations in protein kinases.
Torkamani A; Schork NJ
Cancer Res; 2008 Mar; 68(6):1675-82. PubMed ID: 18339846
[TBL] [Abstract][Full Text] [Related]
12. Single-stranded DNA binding proteins influence APOBEC3A substrate preference.
Brown AL; Collins CD; Thompson S; Coxon M; Mertz TM; Roberts SA
Sci Rep; 2021 Oct; 11(1):21008. PubMed ID: 34697369
[TBL] [Abstract][Full Text] [Related]
13. The Damaging Effect of Passenger Mutations on Cancer Progression.
McFarland CD; Yaglom JA; Wojtkowiak JW; Scott JG; Morse DL; Sherman MY; Mirny LA
Cancer Res; 2017 Sep; 77(18):4763-4772. PubMed ID: 28536279
[TBL] [Abstract][Full Text] [Related]
14. Biochemical analysis of hypermutation by the deoxycytidine deaminase APOBEC3A.
Love RP; Xu H; Chelico L
J Biol Chem; 2012 Aug; 287(36):30812-22. PubMed ID: 22822074
[TBL] [Abstract][Full Text] [Related]
15. Comprehensive Analyses Identify APOBEC3A as a Genomic Instability-Associated Immune Prognostic Biomarker in Ovarian Cancer.
Xu F; Liu T; Zhou Z; Zou C; Xu S
Front Immunol; 2021; 12():749369. PubMed ID: 34745121
[TBL] [Abstract][Full Text] [Related]
16. A Tumor-Promoting Phorbol Ester Causes a Large Increase in APOBEC3A Expression and a Moderate Increase in APOBEC3B Expression in a Normal Human Keratinocyte Cell Line without Increasing Genomic Uracils.
Siriwardena SU; Perera MLW; Senevirathne V; Stewart J; Bhagwat AS
Mol Cell Biol; 2019 Jan; 39(1):. PubMed ID: 30348839
[TBL] [Abstract][Full Text] [Related]
17. Using passenger mutations to estimate the timing of driver mutations and identify mutator alterations.
Youn A; Simon R
BMC Bioinformatics; 2013 Dec; 14():363. PubMed ID: 24330428
[TBL] [Abstract][Full Text] [Related]
18. APOBEC3A/B-induced mutagenesis is responsible for 20% of heritable mutations in the TpCpW context.
Seplyarskiy VB; Andrianova MA; Bazykin GA
Genome Res; 2017 Feb; 27(2):175-184. PubMed ID: 27940951
[TBL] [Abstract][Full Text] [Related]
19. APOBEC3A and APOBEC3B Activities Render Cancer Cells Susceptible to ATR Inhibition.
Buisson R; Lawrence MS; Benes CH; Zou L
Cancer Res; 2017 Sep; 77(17):4567-4578. PubMed ID: 28698210
[TBL] [Abstract][Full Text] [Related]
20. Prospectively defined patterns of APOBEC3A mutagenesis are prevalent in human cancers.
DeWeerd RA; Németh E; Póti Á; Petryk N; Chen CL; Hyrien O; Szüts D; Green AM
Cell Rep; 2022 Mar; 38(12):110555. PubMed ID: 35320711
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
